| pubmed-article:8708716 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0239307 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0029246 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0035168 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C1709059 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0205088 | lld:lifeskim |
| pubmed-article:8708716 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:8708716 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:8708716 | pubmed:dateCreated | 1996-9-6 | lld:pubmed |
| pubmed-article:8708716 | pubmed:abstractText | Methotrexate (MTX) has been described to modulate the activity of fluorouracil (5-FU) in patients with metastatic colorectal cancer. The European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Cooperative Group (GITCCG) conducted a phase III trial to investigate the efficacy and tolarability of the addition of low-dose MTX (40 mg/m2) to high-dose infusional 5-FU (60 mg/kg over 48 hours) given weekly for 4 weeks and thereafter every 2 (for 4 weeks) and 3 weeks. | lld:pubmed |
| pubmed-article:8708716 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8708716 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708716 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8708716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708716 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8708716 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8708716 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:DalmarkMM | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:BleibergHH | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:BusetMM | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:WilkBB | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:BlijhamGG | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:WagenerTT | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:CollettiPP | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:LacaveAA | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:de GreveJJ | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:SahmoudTT | lld:pubmed |
| pubmed-article:8708716 | pubmed:author | pubmed-author:SelleslagJJ | lld:pubmed |
| pubmed-article:8708716 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8708716 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:8708716 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8708716 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8708716 | pubmed:pagination | 2266-73 | lld:pubmed |
| pubmed-article:8708716 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:meshHeading | pubmed-meshheading:8708716-... | lld:pubmed |
| pubmed-article:8708716 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8708716 | pubmed:articleTitle | Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. | lld:pubmed |
| pubmed-article:8708716 | pubmed:affiliation | European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group, Brussels, Belgium. | lld:pubmed |
| pubmed-article:8708716 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8708716 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8708716 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8708716 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:8708716 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8708716 | lld:pubmed |
